Want to see HK:1873 full AI Analyst Report?
Viva Biotech Holdings (1873) AI Stock Analysis
Top Page
Viva Biotech Holdings
(HKEX:1873)
The score is primarily driven by improved profitability and a healthier leverage profile, partially offset by declining revenue and weakening 2025 cash-flow momentum. Technicals are supportive with price above key moving averages and positive MACD, while valuation is only moderate with a mid-range P/E and no dividend data.
Viva Biotech Holdings (1873) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 2.58B
- Dividend Yield
- ―
- Average Volume (3M)
- 5.75M
- Price to Earnings (P/E)
- 12.9
- Beta (1Y)
- 1.93
- Revenue Growth
- 7.38%
- EPS Growth
- 7.90%
- Country
- Hong Kong
- Employees
- 2,213
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Viva Biotech Holdings Business Overview & Revenue Model
Company Description
Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, operates as an investment holding company primarily dedicated to providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients worldwi...
How the Company Makes Money
Viva Biotech primarily makes money by providing fee-for-service research and development work to external customers and recognizing revenue under service contracts. Key revenue streams include: (1) Contract research services: clients pay for outsourc...
Viva Biotech Holdings Financial Statement Overview
Summary
Income statement shows a meaningful return to profitability (2024–2025) with stable mid-30% gross margin and low-teens operating margin, and the balance sheet has improved leverage (debt-to-equity down to ~one-third). However, multi-year revenue decline (including -8.3% in 2025) and a sharp 2025 free-cash-flow drop (~59% YoY) reduce confidence in durability of the turnaround.
Income Statement
62PositiveBalance Sheet
70PositiveCash Flow
48Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.89B | 1.73B | 1.99B | 2.16B | 2.38B | 2.10B |
| Gross Profit | 653.15M | 655.56M | 687.40M | 738.43M | 815.68M | 650.98M |
| EBITDA | 392.81M | 404.30M | 443.53M | 403.90M | 451.35M | 390.06M |
| Net Income | 176.93M | 219.76M | 167.29M | -116.11M | -528.48M | 287.55M |
Balance Sheet | ||||||
| Total Assets | 6.89B | 7.20B | 7.05B | 7.45B | 7.92B | 8.04B |
| Cash, Cash Equivalents and Short-Term Investments | 1.06B | 1.13B | 941.58M | 1.04B | 678.57M | 800.95M |
| Total Debt | 897.96M | 1.33B | 1.28B | 1.90B | 2.82B | 2.65B |
| Total Liabilities | 2.92B | 3.19B | 3.23B | 3.76B | 4.32B | 4.13B |
| Stockholders Equity | 3.96B | 4.00B | 3.80B | 3.69B | 3.60B | 3.91B |
Cash Flow | ||||||
| Free Cash Flow | 284.60M | 88.02M | 182.32M | 195.57M | 136.72M | -487.35M |
| Operating Cash Flow | 427.35M | 206.04M | 373.99M | 383.40M | 386.05M | 77.83M |
| Investing Cash Flow | 46.96M | -93.76M | 185.90M | 439.17M | -372.80M | -868.84M |
| Financing Cash Flow | -356.38M | 36.61M | -657.76M | -429.50M | -143.20M | -653.16M |
Viva Biotech Holdings Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1873, the sentiment is Negative. The current price of 1.25 is below the 20-day moving average (MA) of 1.41, below the 50-day MA of 1.42, and below the 200-day MA of 1.64, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 40.47 is Neutral, neither overbought nor oversold. The STOCH value of 30.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1873.
Viva Biotech Holdings Peers Comparison
Overall Rating
HK:226981Outperform
HK:154871Outperform
HK:231569Neutral- HK:187364Neutral
HK:682154Neutral
HK:375953Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2269 | 81Outperform | HKD 183.11B | 31.19 | 10.51% | ― | 21.93% | 21.94% |
| HK:1548 | 71Outperform | HKD 79.58B | -14.95 | -16.23% | ― | 53.48% | -120.02% |
| HK:2315 | 69Neutral | HKD 17.02B | 38.23 | 15.94% | ― | 48.04% | 166.72% |
| HK:1873 | 64Neutral | HKD 2.60B | 12.92 | 4.45% | ― | 7.38% | 7.90% |
| HK:6821 | 54Neutral | HKD 54.78B | 40.79 | 6.66% | 1.44% | 23.95% | 18.73% |
| HK:3759 | 53Neutral | HKD 80.45B | 41.79 | 10.93% | 0.85% | 24.21% | 19.72% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1873 | Viva Biotech Holdings | 1.25 | -1.14 | -47.70% | |
| HK:1548 | Genscript Biotech Corporation | 35.02 | 17.98 | 105.52% | |
| HK:2269 | Wuxi Biologics (Cayman) | 44.48 | 8.86 | 24.87% | |
| HK:3759 | Pharmaron Beijing Co., Ltd. Class H | 26.98 | 1.65 | 6.50% | |
| HK:2315 | Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H | 38.30 | 9.06 | 30.98% | |
| HK:6821 | Asymchem Laboratories (Tianjin) Co., Ltd. Class H | 103.90 | 19.42 | 22.99% |
Viva Biotech Holdings Corporate Events
Viva Biotech grows revenue but faces profit margin squeeze in first half of 2026
Viva Biotech Holdings reported interim unaudited results for the six months ended June 30, 2026, showing revenue of RMB1,006.5 million, up from RMB831.9 million a year earlier, while gross profit was broadly flat at RMB341.7 million and gross margin...
Viva Biotech Sets Board Meeting to Approve Interim Results and Mull Dividend
Viva Biotech Holdings has scheduled a board meeting for August 26, 2026 to review and approve the interim financial results for the six months ended June 30, 2026. The board will also consider the possible declaration of an interim dividend, signalin...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 08, 2026